Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.

Michael PaulzenEkkehard HaenChristoph HiemkeBenedikt StegmannSarah E LammertzGerhard GründerGeorgios Schoretsanitis

Published in: British journal of clinical pharmacology (2017)

The coadministration of perazine in RIS-medicated patients leads to significantly higher plasma concentrations and C/D values of RIS and its active moiety, and a lower metabolic ratio, reflecting the cytochrome P450 (CYP) 2D6 phenotype. We suggest that the mechanism underlying the effect of perazine on RIS metabolism is based on an inhibition of CYP2D6 and CYP3A4 activity.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
emergency department
adverse drug
electronic health record